Research programme: neurodegenerative disease therapeutics - Baylor College of Medicine/UCB

Drug Profile

Research programme: neurodegenerative disease therapeutics - Baylor College of Medicine/UCB

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Baylor College of Medicine; UCB
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 09 Feb 2016 Early research in Neurodegenerative disorders in USA and Belgium (unspecified route)
  • 09 Feb 2016 UCB and Baylor College of Medicine agree to co-promote and co-develop Neurodegenerative disease therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top